Abstract
Background: The recent novel coronavirus disease 2019 (COVID-19) pandemic has underlined the importance of risk score models in public health emergencies. This study aimed to develop a risk prediction score to identify high-risk hospitalized patients for disease progression on admission. Methods: This prospective cohort study included 171 COVID-19 patients, identified through the reverse transcription polymerase chain reaction test, admitted to Bohlool Hospital in Gonabad City, Iran, between April 4 and June 5, 2021. The patients’ demographic, clinical, and laboratory data were collected upon admission, and clinical outcomes were monitored until the end of the study. The discovery dataset (80% of the data) was used to develop the risk score model based on clinical and laboratory features and patient characteristics to predict COVID-19 progression. An additive risk score model was developed based on the regression coefficients of the significant variables in a multiple logistic regression model. The performance of the risk score model was evaluated on the validation dataset (20% of the data) using the receiver operating characteristic (ROC) curve. Statistical analyses were performed with SPSS software, version 21. Results: The Mean±SD for age of participants was 59.54±20.52 years, and 48.6% were male. Most patients (82.5%) fully recovered or showed improvement, while 5.2% experienced disease progression and 12.3% died. Three variables, interleukin-6, neutrophil-to-lymphocyte ratio, and lung involvement, were found to be significant in predicting risk, with a good discriminatory ability, having an area under the ROC curve of 0.970 (95% CI, 0.935%, 1.00%) in the discovery set and 0.973 (95% CI, 0.923%, 1.00%) in the validation set. Conclusion: The developed risk score model in this study can be used as a clinical diagnostic tool to identify COVID-19 patients at higher risk of disease progression and aid in informed decision-making and resource utilization in similar situations, such as respiratory disease outbreaks in the post-corona era.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.